Americans' attitudes toward psychiatric medications: 1998-2006

Psychiatric Services

Volumn 60, Issue 8, 2009, Pages 1015-1023

  Mojtabai, Ramin ^a  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; NEUROLEPTIC AGENT;

ARTICLE; ATTITUDE; COPING BEHAVIOR; FAMILY RELATION; HEALTH SURVEY; MAJOR DEPRESSION; MENTAL STRESS; PANIC; PSYCHIATRIC TREATMENT; PUBLIC OPINION; RISK; SCHIZOPHRENIA;

EID: 69149111438     PISSN: 10752730     EISSN: 15579700     Source Type: Journal    
DOI: 10.1176/ps.2009.60.8.1015     Document Type: Article

References (34)

1. Mojtabai R: Increase in antidepressant medication in the US adult population between 1990 and 2003. Psychotherapy and Psychosomatics 77:83-92, 2008
2. Baldessarini RJ, Tondo L, Strombom IM, et al: Ecological studies of antidepressant treatment and suicidal risks. Harvard Review of Psychiatry 15:133-145, 2007 (Pubitemid 47237774)
3. Mojtabai R: Americans' attitudes toward mental health treatment seeking: 1990-2003. Psychiatric Services 58:642-651, 2007
4. Angermeyer MC, Matschinger H: Have there been any changes in the public's attitudes towards psychiatric treatment? Results from representative population surveys in Germany in the years 1990 and 2001. Acta Psychiatrica Scandinavica 111:68-73, 2005
5. Jorm AF, Christensen H, Griffiths KM: The public's ability to recognize mental disorders and their beliefs about treatment: changes in Australia over 8 years. Australian and New Zealand Journal of Psychiatry 40:36-41, 2006 (Pubitemid 43337438)
6. Jorm AF, Angermeyer MC, Katschnig H: Public knowledge of and attitudes to mental disorders: a limiting factor in the optimal use of treatment services; in Unmet Need in Psychiatry. Edited by Andrews G, Henderson S. Cambridge, United Kingdom, Cambridge University Press, 2000
7. Kessler RC, Demler O, Frank RG, et al: Prevalence and treatment of mental disorders, 1990 to 2003. New England Journal of Medicine 352:2515-2523, 2005
8. Paulose-Ram R, Safran MA, Jonas BS, et al: Trends in psychotropic medication use among US adults. Pharmacoepidemiology and Drug Safety 16:560-570, 2007 (Pubitemid 46824278)
9. Donohue JM, Cevasco M, Rosenthal MB: A decade of direct-to-consumer advertising of prescription drugs. New England Journal of Medicine 357:673-681, 2007 (Pubitemid 47267237)
10. Kravitz RL, Epstein RM, Feldman MD, et al: Influence of patients' requests for direct-to-consumer advertised antidepressants: a randomized controlled trial. JAMA 293:1995-2002, 2005
11. Jureidini JN, Doecke CJ, Mansfield PR, et al: Efficacy and safety of antidepressants for children and adolescents. British Medical Journal 328:879-883, 2004 (Pubitemid 38471402)
12. Lieberman JA, Stroup TS, McEvoy JP, et al: Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. New England Journal of Medicine 353:1209-1223, 2005 (Pubitemid 41345943)
13. Gibbons RD, Brown CH, Hur K, et al: Early evidence on the effects of regulators' suicidality warnings on SSRI prescriptions and suicide in children and adolescents. American Journal of Psychiatry 164:1356-1363, 2007 (Pubitemid 47461135)
14. Simon GE, Savarino J: Suicide attempts among patients starting depression treatment with medications or psychotherapy. American Journal of Psychiatry 164:1029-1034, 2007 (Pubitemid 47121391)
15. DeAngelis CD, Fontanarosa PB: Impugning the integrity of medical science: the adverse effects of industry influence. JAMA 299:1833-1835, 2008
16. Harris G: Top psychiatrist didn't report drug makers' pay. New York Times, Oct 4, 2008, p A1
17. Croghan TW, Tomlin M, Pescosolido BA, et al: American attitudes toward and willingness to use psychiatric medications. Journal of Nervous and Mental Disease 191:166-174, 2003 (Pubitemid 36323957)
18. Davis JA, Smith TW, Marsden PV: General Social Surveys: 1972-1998. Chicago, National Opinion Research Center, 1998
19. Angermeyer MC, Breier P, Dietrich S, et al: Public attitudes toward psychiatric treatment: an international comparison. Social Psychiatry and Psychiatric Epidemiology 40:855-864, 2005 (Pubitemid 41662413)
20. Stata Statistical Software, Release 10. College Station, Tex, Stata Corp, 2008
21. Jeffords JM: Direct-to-consumer drug advertising: you get what you pay for. Health Affairs Web Exclusives W4-253-255, 2004
22. Woloshin S, Schwartz LM, Tremmel J, et al: Direct-to-consumer advertisements for prescription drugs: what are Americans being sold? Lancet 358:1141-1146, 2001
23. Kaphingst KA, Dejong W, Rudd RE, et al: A content analysis of direct-to-consumer television prescription drug advertisements. Journal of Health Communication 9:515-528, 2004 (Pubitemid 40115880)
24. Healy D: Let Them Eat Prozac: The Unhealthy Relationship Between the Pharmaceutical Industry and Depression. New York, New York University Press, 2006
25. Anderson IM: Selective serotonin reuptake inhibitors versus tricyclic antidepressants: a meta-analysis of efficacy and tolerability. Journal of Affective Disorders 58:19-36, 2000 (Pubitemid 30173208)
26. Arroll B, Macgillivray S, Ogston S, et al: Efficacy and tolerability of tricyclic antidepressants and SSRIs compared with placebo for treatment of depression in primary care: a meta-analysis. Annals of Family Medicine 3:449-456, 2005 (Pubitemid 41512663)
27. Paykel ES, Hart D, Priest RG: Changes in public attitudes to depression during the Defeat Depression Campaign. British Journal of Psychiatry 173:519-522, 1998 (Pubitemid 28557135)
28. Jorm AF, Christensen H, Griffiths KM: The impact of Beyondblue: The National Depression Initiative on the Australian public's recognition of depression and beliefs about treatments. Australian and New Zealand Journal of Psychiatry 39:248-254, 2005 (Pubitemid 40601663)
29. Jacobs DG: National Depression Screening Day: Educating the public, reaching those in need of treatment, and broadening professional understanding. Harvard Review of Psychiatry 3:156-159, 1995
30. Olfson M, Guardino M, Struening E, et al: Barriers to the treatment of social anxiety. American Journal of Psychiatry 157:521-527, 2000
31. Olfson M, Marcus SC, Druss B, et al: National trends in the outpatient treatment of depression. JAMA 287:203-209, 2002 (Pubitemid 34251945)
32. Croghan TW: The controversy of increased spending for antidepressants. Health Affairs 20(2):129-135, 2001
33. Druss BG: Rising mental health costs: what are we getting for our money? Health Affairs 25:614-622, 2006
34. Walton SM, Schumock GT, Lee KV, et al: Prioritizing future research on off-label prescribing: results of a quantitative evaluation. Pharmacotherapy 28:1443-1452, 2008